Drug Profile
PSD 509
Alternative Names: M5004; PSD509Latest Information Update: 28 May 2014
Price :
$50
*
At a glance
- Originator Metris Therapeutics
- Developer Plethora Solutions
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 25 Feb 2013 Discontinued - Phase-I for Pain in United Kingdom (Vaginal)
- 24 Jan 2011 No development reported - Phase-I for Pain in United Kingdom (Vaginal)
- 23 Nov 2007 PSD 509 is available for licensing worldwide (http://www.plethorasolutions.co.uk)